Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe

Regenerative medicine now needs to pass a crucial turning point, from academic research to the market. Several sources/types of cells have been experimented with, more or less successfully. CD34(+) cells have demonstrated multipotent or even pluripotent capacities, making them good candidates for re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hénon, Philippe, Kowalczyk, Marc, Aries, Anne, Vignon, Christine, Trébuchet, Guillaume, Lahlil, Rachid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209364/
https://www.ncbi.nlm.nih.gov/pubmed/35420389
http://dx.doi.org/10.1007/s12015-022-10373-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209364/
https://www.ncbi.nlm.nih.gov/pubmed/35420389
http://dx.doi.org/10.1007/s12015-022-10373-5

Ejemplares similares